Korro Bio, Inc.

Korro Bio, Inc. is a clinical-stage biopharmaceutical company developing RNA editing medicines for rare and prevalent diseases. The company is focused on discovering, developing, and commercializing genetic medicines, while relying on third-party manufacturers, CROs, and collaboration partners to advance its pipeline.

−1 839,4 %

−1 834,5 %

+181,5 %

6.90

6.90

— Korro Bio, Inc.
%
RNA editing platform0% Core technology used to design genetic medicines that edit RNA rather than DNA.
Clinical and preclinical programs0% Product candidates and development programs advancing through preclinical and clinical testing.
Collaboration revenue100% Revenue from research collaboration and license agreements, including the Novo Nordisk arrangement.
Delivery technology licensing0% Licensed LNP delivery systems used to improve targeting and delivery of RNA medicines.

Korro Bio does not yet sell approved products, so its current counterparties are collaboration partners, licensors,...

  • Research collaboration partnersprimary

    Pharmaceutical or biotech partners that pay for access to Korro's research and license rights, such as Novo Nordisk.

  • Contract research and manufacturing providersprimary

    CROs and CMOs that buy services from Korro or provide outsourced development and manufacturing support.

  • Future specialty prescribersemerging

    Physicians and treatment centers that would use approved RNA editing medicines in rare or high-prevalence diseases.

  • Payers and reimbursement decision-makersemerging

    Insurers and health systems that would influence uptake by determining coverage and pricing acceptance.

Korro Bio is headquartered in the United States and currently conducts its business through U.S...

  • •Headquartered in the United States
  • •No disclosed product revenue by country
  • •Clinical and manufacturing work relies on third-party partners
  • •Future commercialization may extend to international markets
  • •Current exposure is operational rather than sales-driven

Korro Bio's strategy is to advance RNA editing medicines through preclinical and clinical development while preserving...

01
Advance clinical and IND-enabling programsshort-term

Clinical proof-of-concept is the main value driver for an RNA editing biotech with no product sales.

02
Maintain collaboration fundingshort-term

Partnership revenue helps offset R&D spend and reduces dependence on equity financing.

03
Expand and defend intellectual propertymedium-term

Patent and trade secret protection are central to protecting platform value and negotiating leverage.

04
Preserve optionality on manufacturing and commercializationmedium-term

The company currently lacks commercial manufacturing and sales infrastructure, so it must decide whether to build or partner.

Korro Bio faces the classic risks of a clinical-stage biotech: high R&D burn, uncertain clinical success, and...

critical

Clinical development failure

The company has no approved products, so value depends on successful preclinical and clinical outcomes.

Scope
Pipeline programs and RNA editing candidates
Materiality
high
high

Loss or pause of collaboration revenue

A meaningful portion of current revenue comes from a single collaboration arrangement with Novo Nordisk.

Scope
Research collaboration and license revenue
Materiality
high
high

Manufacturing and supply chain dependence

The company has no commercial manufacturing capabilities and relies on third-party CMOs for critical materials and trial supply.

Scope
IND-supporting activities and early-stage clinical trials
Materiality
high
high

Financing risk

The business expects continued losses and will need additional capital to fund development and commercialization.

Scope
Equity raises, collaborations, and other financing sources
Materiality
high
medium

Intellectual property risk

The platform depends on patent protection, trade secrets, and in-licensed technology to maintain differentiation.

Scope
RNA editing methods, delivery systems, and manufacturing know-how
Materiality
medium
Collaboration and license revenue recognition
Affects collaboration revenue from agreements such as Novo Nordisk
R&D accruals and outsourced development costs
Affects operating expenses and period-end liabilities
Stock-based compensation
Affects reported loss from operations
Fair value of financing instruments
Affects equity classification and non-cash gains or losses

KALA BIO, Inc.

KALA · Pharmaceutical Preparations

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

MUSTANG BIO, INC.

MBIO · Pharmaceutical Preparations

CERO THERAPEUTICS HOLDINGS, INC.

CERO · Biological Products, (No Diagnostic Substances)

Spero Therapeutics, Inc.

SPRO · Pharmaceutical Preparations

GRI Bio, Inc.

GRI · Pharmaceutical Preparations

: 28/04/2026